$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000112623422000066 Filed on May 11, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$111.0K	$220.0K	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.621M	$3.428M	$4.000M
YoY Change	-9.48%	-25.48%	21.21%
% of Gross Profit
Research & Development	$4.221M	$3.361M	$4.660M
YoY Change	-9.42%	34.44%	144.62%
% of Gross Profit
Depreciation & Amortization	$12.00K	$10.00K	$170.0K
YoY Change	-92.94%	-95.0%	1788.89%
% of Gross Profit
Operating Expenses	$7.842M	$6.789M	$8.617M
YoY Change	-8.99%	-4.38%	64.57%
Operating Profit	-$7.731M		-$8.617M
YoY Change	-10.28%		65.23%
Interest Expense	$0.00	$42.00K	$37.00K
YoY Change	-100.0%		-22.92%
% of Operating Profit
Other Income/Expense, Net	$11.00K	$250.0K	-$14.00K
YoY Change	-178.57%		-115.22%
Pretax Income	-$7.720M	-$6.277M	-$8.631M
YoY Change	-10.55%	-11.59%	68.48%
Income Tax	$0.00	-$636.0K	$0.00
% Of Pretax Income
Net Earnings	-$7.720M	-$5.641M	-$8.631M
YoY Change	-10.55%	135.04%	-2638.53%
Net Earnings / Revenue	-6954.95%	-2564.09%
Basic Earnings Per Share	-$0.92		-$1.04
Diluted Earnings Per Share	-$0.92	-$676.5K	-$1.04
COMMON SHARES
Basic Shares Outstanding	8.358M shares	8.357M shares	8.317M shares
Diluted Shares Outstanding	8.358M shares		8.317M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.76M	$94.81M	$114.1M
YoY Change	-23.96%	-3.94%	32.98%
Cash & Equivalents	$86.80M	$94.81M	$114.1M
Short-Term Investments
Other Short-Term Assets	$5.753M	$4.740M	$5.300M
YoY Change	8.55%	35.43%	130.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables		$0.00	$79.00K
Total Short-Term Assets	$92.65M	$99.68M	$119.6M
YoY Change	-22.54%	-22.4%	28.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$69.00K	$79.00K	$100.0K
YoY Change	-31.0%	-76.42%	-90.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$545.0K	$635.0K	$461.0K
YoY Change	18.22%	8.73%	-99.49%
TOTAL ASSETS
Total Short-Term Assets	$92.65M	$99.68M	$119.6M
Total Long-Term Assets	$545.0K	$635.0K	$461.0K
Total Assets	$93.19M	$100.3M	$120.1M
YoY Change	-22.38%	-22.26%	-34.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.799M	$612.0K	$357.0K
YoY Change	403.92%	150.82%	-84.89%
Accrued Expenses	$3.098M	$4.166M	$4.366M
YoY Change	-29.04%	-29.37%	-43.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.242M	$5.130M	$4.984M
YoY Change	5.18%	-20.6%	-89.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.131M	$6.205M	$6.100M
YoY Change	0.51%	3.42%	0.0%
Total Long-Term Liabilities	$6.131M	$6.205M	$6.106M
YoY Change	0.41%	3.42%	-58.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.242M	$5.130M	$4.984M
Total Long-Term Liabilities	$6.131M	$6.205M	$6.106M
Total Liabilities	$11.37M	$11.34M	$11.09M
YoY Change	2.55%	-9.04%	-81.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$104.1M	-$96.42M	-$74.62M
YoY Change	39.56%	46.11%	24.39%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$119.0K	$114.0K	$44.00K
YoY Change	170.45%
Treasury Stock Shares	9.896K shares	9.428K shares	3.377K shares
Shareholders Equity	$81.82M	$88.98M	$109.0M
YoY Change
Total Liabilities & Shareholders Equity	$93.19M	$100.3M	$120.1M
YoY Change	-22.38%	-22.26%	-34.38%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$7.720M	-$5.641M	-$8.631M
YoY Change	-10.55%	135.04%	-2638.53%
Depreciation, Depletion And Amortization	$12.00K	$10.00K	$170.0K
YoY Change	-92.94%	-95.0%	1788.89%
Cash From Operating Activities	-$8.033M	-$5.828M	-$10.41M
YoY Change	-22.85%	-16.74%	214.56%
INVESTING ACTIVITIES
Capital Expenditures		-$13.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$26.00M
YoY Change	-100.0%		-69.12%
Cash From Investing Activities	$0.00	-$13.00K	$26.00M
YoY Change	-100.0%	-87.0%	-69.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$44.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$18.00K	0.000	-$166.0K
YoY Change	-89.16%	-100.0%
NET CHANGE
Cash From Operating Activities	-$8.033M	-5.828M	-$10.41M
Cash From Investing Activities	$0.00	-13.00K	$26.00M
Cash From Financing Activities	-$18.00K	0.000	-$166.0K
Net Change In Cash	-$8.051M	-5.841M	$15.42M
YoY Change	-152.2%	-16.56%	-80.93%
FREE CASH FLOW
Cash From Operating Activities	-$8.033M	-$5.828M	-$10.41M
Capital Expenditures		-$13.00K
Free Cash Flow		-$5.815M
YoY Change		-16.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1111
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-35342
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	LUMOS PHARMA, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	42-1491350
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4200 Marathon Blvd #200
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78756
CY2022Q1	dei	City Area Code CityAreaCode	512
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	215-2630
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2021Q4	us-gaap	Assets Current AssetsCurrent	99677000	USD
CY2022Q1	dei	Trading Symbol TradingSymbol	LUMO
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8369228	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86758000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94809000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5753000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4740000	USD
CY2022Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	134000	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	128000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	92645000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	69000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79000	USD
CY2022Q1	nlnk	Operating Lease Rightof Use Asset Noncurrent OperatingLeaseRightofUseAssetNoncurrent	476000	USD
CY2021Q4	nlnk	Operating Lease Rightof Use Asset Noncurrent OperatingLeaseRightofUseAssetNoncurrent	556000	USD
CY2022Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	545000	USD
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	635000	USD
CY2022Q1	us-gaap	Assets Assets	93190000	USD
CY2021Q4	us-gaap	Assets Assets	100312000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1799000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	612000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3098000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4166000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	345000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	352000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5242000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5130000	USD
CY2022Q1	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2021Q4	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	131000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	205000	USD
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6131000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6205000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	11373000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	11335000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2021Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8368521	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8366819	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8358625	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8357391	shares
CY2022Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	83000	USD
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	83000	USD
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	9896	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	9428	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	119000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	114000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	185994000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	185429000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104141000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96421000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	81817000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	88977000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93190000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100312000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	111000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2022Q1	us-gaap	Revenues Revenues	111000	USD
CY2021Q1	us-gaap	Revenues Revenues	0	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4221000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4660000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3621000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3957000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	7842000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	8617000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7731000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8617000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	37000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7720000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8631000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8357969	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8357969	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8316888	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8316888	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	116572000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1049000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	44000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8631000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	108972000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	88977000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	565000	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7720000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	81817000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7720000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8631000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	565000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1049000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	170000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1002000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1651000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	7000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-70000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	119000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1419000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8033000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10412000	USD
CY2022Q1	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	0	USD
CY2021Q1	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	26000000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26000000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	44000	USD
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	13000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	148000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-166000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8051000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15422000	USD
CY2022Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	74000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94809000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98679000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86758000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114101000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="text-align:justify;text-indent:22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Organization and Nature of operations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this Quarterly Report to “us,” “we,” “our,” the "Company,” or “Lumos” are to Lumos Pharma, Inc. and its wholly-owned subsidiaries. With our principal executive offices located in Austin, Texas and additional executive and administrative offices located in Ames, Iowa, we are engaged in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advancing our clinical program and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">focused on</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identifying, acquiring, developing, and commercializing novel products and new therapies for people with rare diseases on a global level</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for which there is currently a significant unmet need for safe and effective therapies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market (“Nasdaq”) and trades under</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the ticker symbol “LUMO.”</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entered into a business combination (the “Merger”) between</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company, formerly known as NewLink Genetics Corporation (“NewLink”), Cyclone Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NewLink, and Lumos Pharma, Inc., which has since been renamed “Lumos Pharma Sub, Inc.” (“Private Lumos”). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger closed on March 18, 2020, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger Sub merged with and into Private Lumos, with Private Lumos surviving as a wholly-owned subsidiary of the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Merger, the shares of NewLink common stock were adjusted with a reverse split ratio of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1‑for‑9.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of the Merger, Private Lumos stockholders received an aggregate of 4,146,398 shares </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of NewLink common stock (after giving effect to the reverse split)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each share of outstanding common stock, Series A Preferred Stock and Series B Preferred Stock of Private Lumos converted at an exchange ratio of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1308319305, 0.0873621142 and 0.1996348626</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Immediately following the reverse stock split and the completion of the Merger, there were 8,292,803 shares of the Company’s common stock outstanding</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of which approximately 50% was held by each of Private Lumos and NewLink security holders. The Merger was accounted for as a reverse asset acquisition. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the consummation of the Merger, the combined company has focused its efforts on the development of Private Lumos’ sole product candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secretagogue </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ibutamoren (“LUM-201”), a potential oral therapy for pediatric growth hormone deficiency (“PGHD”) and other rare endocrine disorders.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically devoted substantially all of its efforts toward research and development and has never earned revenue from commercial sales of its products. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. However, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company believes that its existing cash and cash equivalents </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$86.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of March 31, 2022 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be sufficient to allow the Company to fund its operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through the primary read out of its Phase 2 clinical trial of LUM-201 in PGHD ("OraGrowtH210 Trial") and OraGrowtH212 Trial and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for at least 12 months from the filing date of this Quarterly Report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If available liquidity becomes insufficient to meet the Company’s obligations as they come due, our f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uture operations will be reliant on additional equity or financing arrangements. There can be no assurances that, in the event that the Company requires additional financing, such financing will be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on terms which are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic caused by an outbreak of a novel strain of coronavirus, SARS-CoV-2, which causes COVID-19 (“COVID-19”), has resulted, and is likely to continue to result, in significant national and global economic disruption and may continue to adversely affect the Company’s operations. COVID-19 restrictions have led to a slower pace of site initiation and patient enrollment in our clinical trials that has delayed the 6-month primary outcome data read out of our OraGrowtH210 Trial. While we have experienced delays to our clinical trials, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we have not incurred impairment of any assets as a result of COVID-19. The extent to which these events may further impact the Company’s business, clinical development, regulatory efforts, and the value of its common stock, will depend on future developments, which are highly uncertain and cannot be predicted at this time. The duration and intensity of these impacts and resulting disruption to the Company’s operations is uncertain, and the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The military conflict between Russia and Ukraine (the “Conflict”), has resulted, and may continue to result, in significant national and global economic disruption and may continue to adversely affect the Company’s operations. The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> had initiated or had planned to initiate clinical sites in Russia and Ukraine; however, due to the Conflict and the resulting uncertainty in the region, the Company is unable to enroll patients in Ukraine and all of its clinical sites in Russia are suspended until further notice. No patients had been randomized to treatment in the clinical trial at any of the Company's nine sites in Ukraine and Russia. Given the encouraging screening and enrollment trajectory at the Company's other clinical sites, the Company continues to anticipate the six-month primary outcome data on all 80 subjects in the second half of 2023. The ongoing Conflict may, however, adversely impact the Company's business in the future, and it remains too early to evaluate all the potential effects of this Conflict.</span>
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8292803	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86800000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’s financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets and liabilities include stock-based compensation, accruals for clinical trials and deferred tax assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that the estimates and assumptions used in preparation of our condensed consolidated financial statements </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on our knowledge of current events and actions that we may undertake in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are appropriate, actual results could differ from those estimates, and any such differences may be material.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company’s significant accounting policies are consistent with those discussed in Note 2 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summary of Significant Accounting Policies and Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span> of its consolidated financial statements included in the Company’s 2021 Annual Report filed on Form 10-K with the SEC on March 11, 2022.
CY2021Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	0	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1481000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2812000	USD
CY2022Q1	nlnk	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	874000	USD
CY2021Q4	nlnk	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	508000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	743000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	846000	USD
CY2022Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3098000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4166000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	565000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1049000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5600000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7720000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8631000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8357969	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8357969	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8316888	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8316888	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1510369	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1230143	shares
CY2021Q1	nlnk	Deferred Compensation Arrangement With Individual Accelerated Vesting Expense DeferredCompensationArrangementWithIndividualAcceleratedVestingExpense	700000	USD
CY2022Q1	nlnk	Deferred Compensation Arrangement With Individual Accelerated Vesting Expense DeferredCompensationArrangementWithIndividualAcceleratedVestingExpense	0	USD

Files In Submission

Name	View Source	Status
0001126234-22-000066-index-headers.html	Edgar Link	pending
0001126234-22-000066-index.html	Edgar Link	pending
0001126234-22-000066.txt	Edgar Link	pending
0001126234-22-000066-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lumo-2022331x10qxex311.htm	Edgar Link	pending
lumo-2022331x10qxex312.htm	Edgar Link	pending
lumo-2022331x10qxex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nlnk-20220331.htm	Edgar Link	pending
nlnk-20220331.xsd	Edgar Link	pending
nlnk-20220331_cal.xml	Edgar Link	unprocessable
nlnk-20220331_def.xml	Edgar Link	unprocessable
nlnk-20220331_g1.jpg	Edgar Link	pending
nlnk-20220331_g2.jpg	Edgar Link	pending
nlnk-20220331_htm.xml	Edgar Link	completed
nlnk-20220331_lab.xml	Edgar Link	unprocessable
nlnk-20220331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2022 Q1 Form 10-Q Financial Statement

#000112623422000066 Filed on May 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2022 Q1 Form 10-Q Financial Statement

#000112623422000066 Filed on May 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo